Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia

Hui Li | Shi-gui Yang | Li Gu | Yao Zhang | Xi-xin Yan | Zong-an Liang | Wei Zhang | Hong-yu Jia | Wei Chen | Meng Liu | Kai-jiang Yu | Chun-xue Xue | Ke Hu | Qi Zou | Lan-juan Li | Bin Cao |  
Chen Wang | for the National Influenza A(H1N1)pdm09 Clinical Investigation Group of China

1Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
2State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
3Global Health, Population & Nutrition, Global Research & Services, Family Health International 360, Durham, NC, USA
4Department of Respiratory Medicine, Second Hospital of Hebei Medical University, Shijiazhuang, China
5West China Hospital of Sichuan University, Chengdu, China
6The First Affiliated Hospital, Nanchang University, Nanchang, China
7Shengjing Hospital of China Medical University, Shenyang, China
8The Second Affiliated Hospital of Harbin Medical University, Harbin, China
9Renmin Hospital of Wuhan University, Wuhan, China
10Fujian Medical University Union Hospital, Fuzhou, China
11Center for Respiratory Diseases China-Japan Friendship Hospital, Beijing, China
12Department of Respiratory Medicine, Capital Medical University, Beijing, China
13National Clinical Research Centre for Respiratory Disease, Beijing, China
14Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China

Background: The effect of corticosteroids on influenza A(H1N1)pdm09 viral pneumonia patients remains controversial, and the impact of dosage has never been studied.

Methods: Using data of hospitalized adolescent and adult patients with influenza A(H1N1)pdm09 viral pneumonia, prospectively collected from 407 hospitals in mainland China, the effects of low-to-moderate-dose (25-150 mg d⁻¹) and high-dose (>150 mg d⁻¹) corticosteroids on 30-day mortality, 60-day mortality, and nosocomial infection were assessed with multivariate Cox regression and propensity score-matched case–control analysis.

Results: In total, 2141 patients (median age: 34 years; mortality rate: 15.9%) were included. Among them, 1160 (54.2%) had PaO₂/FiO₂<300 mm Hg on admission, and 1055 (49.3%) received corticosteroids therapy. Corticosteroids, without consideration
Corticosteroids were widely used in patients with severe influenza infection. The use of corticosteroids is based on the underlying pathogenesis of severe influenza infection, which is characterized by overproduction of proinflammatory cytokines/chemokines\(^1,2\) and an excess of activated lymphocytes,\(^3\) which may result in severe lung damage\(^4,5\) and delayed recovery.\(^6\) Moreover, animal model studies also found that corticosteroid treatment decreased mortality and ameliorated the acute lung injury induced by influenza A(H1N1)pdm09 virus.\(^7,8\) Although corticosteroids are posited to be beneficial in the treatment of severe influenza patients, clinical results remain contradictory and opposition overwhelms support in studies published so far.\(^9\)–\(^17\) It is reported that corticosteroid might impair viral clearance and increase secondary infection.\(^13,18,19\) The major guidelines recommend avoiding the use of systemic corticosteroids beyond special occasions such as adrenal insufficiency and severe COPD.\(^20\)

This discrepancy between the “reality” and theory might be translated to the following conditions. First, corticosteroid is definitely not effective at all for all influenza patients due to its side effects. Second, the truth is covered by some confounders, due to that corticosteroid tends to be given to more severe patients. Third, corticosteroid might be only effective at a certain dosage for a specific group of influenza patients who are characterized with severe cytokine storm. However, it is not useful or even harmful for patients otherwise. Therefore, the additive effect on mortality of all patients might be neutral or even harmful, as previously reported.\(^17,21\)

Although the benefits of corticosteroids therapy were recently reported in randomized controlled trials (RCT) and observational studies in patients with severe community-acquired pneumonia,\(^22,24\) no RCT about the effect of corticosteroids on mortality of influenza-infected patients has been completed. The majority of researches published so far are retrospective observational studies,\(^12,14,25,26\) and most of them involved a relatively small sample. Although meta-analysis could counteract the small sample size, lack of consistency between studies would preclude any firm conclusions.\(^17,21\) Moreover, drug dosage was not clearly demonstrated.\(^17,21\) Studies on acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) revealed that low-to-moderate dose corticosteroids reduced mortality significantly,\(^31,32\) but high-dose (>2.0 mg·kg\(^{-1}\)·d\(^{-1}\)methylprednisolone) corticosteroid therapy had no such benefits.\(^31\) However, the effect of low-to-moderate-dose corticosteroids on patients with influenza A(H1N1)pdm09 viral pneumonia has not been determined.

Using the largest nationwide database,\(^33,34\) comprising of 2141 hospitalized adolescent and adult patients with influenza A(H1N1)pdm09 viral pneumonia, we explored the effect of different doses of adjuvant corticosteroid therapy on mortality of these patients with different disease severity.

## 2 METHODS

### 2.1 Study population and data collection

This study was a retrospective database analysis approved by the research ethics committee of Beijing Chao-Yang Hospital (10-ke-17). Requirement for written informed patient content was waived, because all data were anonymous.

Data was collected prospectively from September 1, 2009 to December 31, 2009, under the surveillance of the Ministry of Health, which has been clearly described in our previous studies.\(^34\) For each patient, influenza A(H1N1)pdm09 viral infection was confirmed by polymerase chain reaction (PCR) from nasopharyngeal swab, sputum, or bronchoalveolar lavage fluid. To ensure accuracy, data were rechecked before analysis by two independent researchers.
2.2 | Endpoints and definitions

Patients aged >14 years with influenza A(H1N1)pdm09 viral pneumonia and complete clinical information were included in the analysis. The primary outcome under investigation was all-cause mortality within 30 days of disease onset (30-day mortality). The secondary outcomes included mortality within 60 days (60-day mortality) and nosocomial infection.

Pneumonia was defined as an acute lower respiratory illness with an opacity or infiltrate seen on chest radiography, which was interpreted as pneumonia by the treating physician.29 Nosocomial infection was diagnosed when a positive culture of a new pathogen was obtained from a lower respiratory tract specimen (sputum, bronchial/tracheal aspirates, or bronchoalveolar lavage fluid) and/or blood samples taken ≥48 hours after admission.30 Invasive pulmonary aspergillosis and mucormycosis were diagnosed in accordance with the revised definitions of invasive fungal diseases from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.31 Systemic corticosteroid treatment was defined as any intended therapeutic use of corticosteroids, including methylprednisolone, prednisolone, dexamethasone, and/or hydrocortisone by oral or intravenous routes during the disease course, but excluding inhalational therapy. Low-to-moderate-dose corticosteroids were defined as 25-150 mg d−1 methylprednisolone or equivalent, while high-dose corticosteroids were defined as >150 mg d−1 methylprednisolone or equivalent.24,31,32 Patients without corticosteroid treatment were classified as the control group. Neuraminidase inhibitor (NAI) treatment referred to administration of any dose of oseltamivir, zanamivir, and/or peramivir during hospitalization.

2.3 | Study design and statistical analysis

Continuous variables were summarized as medians (interquartile ranges). For categorical variables, the percentage of patients in each category was calculated. Clinical characteristics were compared between patients who received systemic corticosteroid (corticosteroids) and those not (no corticosteroids), using the Mann-Whitney U test and chi-squared test as appropriate.

Independent factors were determined by multivariate Cox regression models, including all covariates with P<.20 selected from a predetermined list (Table 1) by means of forward logistic regression. The probability for the entry and stepwise removal was 0.05 and 0.10, respectively. All these independent factors were further used to adjust the effects of systemic corticosteroids. Subgroup analysis was performed for patients with influenza A(H1N1)pdm09 viral pneumonia with PaO2/FiO2 <100 mm Hg and PaO2/FiO2 ≥300 mm Hg on admission.

To minimize the effect of selection bias, we further performed one-to-one matching, based on propensity score analysis between patients with low-to-moderate-dose corticosteroids and control, and between patients with high-dose corticosteroids and control. The propensity scores were determined using multiple logistic regression without regard to outcome. All pre-specified co-variables related to the propensity for mortality or for receiving corticosteroids were included in the final models. C-statistics was used to assess model discrimination. To develop propensity score-matched pairs without replacement (a 1:1 match), the greedy 5 to 1 digit match algorithm was used, as previously described.33 We assessed the balance of baseline covariates between the two treatment groups using the Wilcoxon signed-rank test for continuous variables and McNemar’s test for binary categorical variables. In the propensity-matched cohort, the Kaplan-Meier method with log-rank testing was used to assess differences in mortality between corticosteroid groups and controls.

All tests were two-tailed, with the significance level set at 0.05. All analyses were carried out using SPSS software for Windows (release 17.0) and SAS version 9.1 (SAS Institute, Cary, NC).

3 | RESULTS

3.1 | Clinical characteristics of the cohort

During the 4-month study period, 2415 hospitalized patients with influenza A(H1N1)pdm09 viral pneumonia were registered, of which 274 were excluded for lack of important clinical information or because of duplicate entries (Figure 1). Altogether, 2141 hospitalized cases from 407 hospitals in 27 provinces or municipalities in mainland China were enrolled for final analysis (Table S1).

The median age of the cohort was 34.4 years, and 89% of all the patients were younger than 60 years. The patients were hospitalized within a median duration of 5 days after disease onset, and PaO2/FiO2 on admission was <300 mm Hg in 54.2% of these patients. The mortality rates of patients with PaO2/FiO2 <100 mm Hg, 100-200 mm Hg, 200-300 mm Hg, and ≥300 mm Hg were 48.4%, 23.8%, 16.9%, and 3.5%, respectively. At least one type of antibiotic was administered to 97.7% patients on admission. Oseltamivir was the only NAI used and was given to 95.6% patients within a median duration of 6 days after disease onset (Table 1).

3.2 | Corticosteroid treatment

Among the 2141 enrolled patients, 1055 (49.3%) received corticosteroid treatment, among whom 939 (89%) patients were administered methylprednisolone, 85 (8.1%) dexamethasone, and 21(2.0%) hydrocortisone. Of them, 662 patients received low-to-moderate-dose corticosteroids and 367 cases received high-dose corticosteroids (Figure 1). Corticosteroids were initiated within 6 (IQR 4-8) days after the onset of illness, that is, within 48 hours of admission; baseline values of time-dependent variables could thus be substituted with values on admission. Patients were treated with corticosteroids for a median duration of 7 (IQR 4-8) days (Table 2).

3.3 | Effect of corticosteroids on mortality by Cox regression analysis

Univariate analysis (Table S2) showed that many factors other than corticosteroid treatment were correlated with mortality, such as...
TABLE 1 Characteristics of 2141 patients hospitalized with influenza A(H1N1)pdm09 viral pneumonia stratified according to the patients’ corticosteroids status

|                          | All patients (n=2141) | Corticosteroids (n=1055) | No corticosteroids (n=1086) | P-value<sup>a</sup> |
|--------------------------|-----------------------|--------------------------|-----------------------------|----------------------|
| **Hospital category**    |                       |                          |                             |                      |
| Secondary hospital       | 254 (11.9)            | 117 (11.1)               | 137 (12.6)                  | .275                 |
| Tertiary hospital        | 1887 (88.1)           | 938 (88.9)               | 949 (87.4)                  |                      |
| **Age, year**            |                       |                          |                             |                      |
| 14-20                    | 271 (12.7)            | 162 (14.9)               | 109 (10.3)                  | <.001                |
| 21-40                    | 1049 (49)             | 481 (44.3)               | 568 (53.8)                  |                      |
| 41-60                    | 579 (27)              | 306 (28.2)               | 273 (25.9)                  |                      |
| 61-80                    | 218 (10.2)            | 124 (11.4)               | 94 (8.9)                    |                      |
| >80                      | 24 (1.1)              | 13 (1.2)                 | 11 (1.0)                    |                      |
| **Female**               | 1046 (48.9)           | 525 (49.8)               | 521 (48.0)                  | .408                 |
| **Underlying diseases**  |                       |                          |                             |                      |
| Hypertension             | 326 (15.2)            | 158 (15.0)               | 168 (15.5)                  | .751                 |
| Diabetes                 | 168 (7.8)             | 78 (7.4)                 | 90 (8.3)                    | .442                 |
| Cardiovascular disease<sup>b</sup> | 131 (6.1) | 56 (5.3) | 75 (6.9) | .123 |
| COPD                     | 106 (5)               | 59 (5.6)                 | 47 (4.3)                    | .177                 |
| Asthma                   | 38 (1.8)              | 22 (2.1)                 | 16 (1.5)                    | .284                 |
| Chronic renal disease    | 74 (3.5)              | 36 (3.4)                 | 38 (3.5)                    | .913                 |
| Malignancy<sup>c</sup>   | 54 (2.5)              | 28 (2.7)                 | 26 (2.4)                    | .701                 |
| Immunosuppressive conditions<sup>d</sup> | 49 (2.3) | 34 (3.2) | 15 (1.4) | .004 |
| Pregnancy or post-partum | 452 (21.1)            | 270 (25.6)               | 182 (16.8)                  | <.001                |
| **Main laboratory findings on admission** |                       |                          |                             |                      |
| Leukocytosis             | 345/2092 (16.5)       | 191/1037 (18.4)          | 154/1055 (14.6)             | .019                 |
| Leukocytopenia           | 527/2092 (25.2)       | 267/1037 (25.7)          | 260/1055 (24.6)             | .578                 |
| Lymphocytopenia          | 852/2009 (42.4)       | 541/994 (54.4)           | 311/1015 (30.6)             | <.001                |
| Hemoglobin, g/L          | 128 (108-144)         | 127 (105-145)            | 129 (109-143)               | .091                 |
| Platelets, 10<sup>9</sup>/L | 152 (113-200)      | 141 (104-187)            | 163 (125-209)               | <.001                |
| Creatinine, μmol/L      | 70 (54.5-88)          | 69 (54-90)               | 70.9 (55.3-86.8)            | .951                 |
| PaO<sub>2</sub>/FiO<sub>2</sub>, mm Hg | 219.5 (127.9-326.4) | 173.3 (100-272.4)        | 286.2 (191.7-388.2)         | <.001                |
| Alanine aminotransferase, U/L | 29 (17-51)       | 35 (21-62.3)             | 24 (15-43)                  | <.001                |
| Lactate dehydrogenase, U/L | 316 (213-542)     | 439 (269-724)            | 257 (184-373)               | <.001                |
| Shock                    | 131/2132 (6.1)        | 84/1052 (8.0)            | 47/1080 (4.4)               | <.001                |
| Invasive mechanical ventilation | 416 (19.4)  | 367 (34.8)               | 49 (4.5)                    | <.001                |
| NAI treatment            | 2047 (95.6)           | 1025 (97.2)              | 1022 (94.1)                 | .001                 |
| Interval between symptom onset and NAI treatment, days | 6 (4-7) | 6 (4-8) | 5 (3-7) | <.001 |
| Interval between symptom onset and hospitalization, days | 5 (3-7) | 5 (4-7) | 5 (3-7) | <.001 |
| Antibiotics              | 2092 (97.7)           | 1037 (98.3)              | 1055 (97.1)                 | .076                 |
| ICU admission            | 960 (44.8)            | 678 (64.3)               | 282 (26.0)                  | <.001                |
| 30-day mortality         | 306 (14.3)            | 232 (22.0)               | 74 (6.8)                    | <.001                |
| 60-day mortality         | 337 (15.7)            | 261(24.7)                | 76 (7.0)                    | <.001                |

COPD, chronic obstructive pulmonary disease; NAI, Neuraminidase inhibitors.
Continuous variables are summarized as median (interquartile range), and categorical variables are presented as number (percentage).
<sup>a</sup>Mann-Whitney U-tests for continuous variables and the chi-squared tests for categorical variables.
<sup>b</sup>Cardiovascular disease: including congestive heart disease, coronary atherosclerotic heart disease, and valvular heart disease.
<sup>c</sup>Malignancy: cancer or hematologic malignancy.
<sup>d</sup>Immunosuppressive condition: chemotherapy or radiotherapy within 1 mo before the onset of illness, or glucocorticoid therapy (equivalent of 30 mg of prednisone per day for 15 continuous days before the onset of illness).
underlying comorbidities, baseline disease severity, NAI treatment, and time duration from disease onset to hospitalization. Covariates (Table 1) with \( P < .20 \) were included in the Cox regression model to determine independent risk factors, all of which were further used to adjust the effect of systemic corticosteroids. Corticosteroids, without consideration of dose, did not influence either the 30-day or 60-day mortality. Further analysis showed that, as compared with the control group, low-to-moderate-dose corticosteroids could reduce the 30-day mortality of patients with influenza A(H1N1)pdm09 viral pneumonia (adjusted hazard ratio [aHR] 0.64 [95% CI 0.43-0.96, \( P = .033 \)), while the 60-day mortality was similar between the two dosage groups and control (Table 3).

In the subgroup analysis for patients with PaO\(_2/\)FiO\(_2\) \( \geq 300 \) mm Hg, corticosteroid therapy resulted in increased 60-day mortality (aHR 3.02 [95% CI 1.06-8.58]). In contrast, for patients with PaO\(_2/\)FiO\(_2\) < 300 mm Hg, low-to-moderate-dose corticosteroids significantly reduced both 30-day mortality (aHR 0.49 [95% CI 0.32-0.77]) and 60-day mortality (aHR 0.51 [95% CI 0.33-0.78]), while these patients did not benefit from high-dose corticosteroids treatment (Table 3). To further overcome the immortal time bias, a time-dependent covariate Cox regression analysis was conducted with the time duration from disease onset to initiation of corticosteroid treatment being considered, and we obtained similar results (Table S3). In the sensitivity analysis, 722 patients who had potential indications for corticosteroid treatment that may have skewed the results, including asthma, COPD exacerbation, pregnancy/post-partum, immunosuppressive conditions, or shock, were excluded, but similar results were obtained (Table S4).

### TABLE 2  Details of corticosteroid administration in 1055 hospitalized patients with influenza A(H1N1)pdm09 viral pneumonia

| Variables                                      | Values       |
|------------------------------------------------|--------------|
| Drug administered, n (%)                       |              |
| Methylprednisolone                             | 939 (89.0)   |
| Dexamethasone                                  | 85 (8.1)     |
| Hydrocortisone                                 | 21 (2.0)     |
| Prednisolone                                   | 10 (0.9)     |
| Daily dose (equivalent methylprednisolone), mg d\(^{-1}\) | 141.3±142   |
| Mean±SD                                        | 141.3±142    |
| Median (IQR)                                   | 80 (53.3-160)|
| Time to initiation from the onset of illness, days | 6.7±4      |
| Mean±SD                                        | 6.7±4        |
| Median (IQR)                                   | 6 (4-8)      |
| Duration of therapy, days                      |              |
| Mean±SD                                        | 7.7±6.8      |
| Median (IQR)                                   | 7 (4-8)      |

SD, standard deviation; IQR, interquartile range.
3.4 | Propensity score-matched case-control analysis of the effect of corticosteroids on mortality

Propensity scores were calculated using a multivariate logistic regression model that included all the factors listed in Table S5 and Table S6, except for the outcomes, and C-statistics was 0.839, indicating good model discrimination. Then, 265 propensity score-matched pairs (Table S5) were generated from the low-to-moderate-dose corticosteroid group (n=662) and control group (n=1086). In the high-dose corticosteroid group (n=367), 148 patients were matched to 148 cases from the control group (Table S6). The baseline characteristics and treatment regimens except for corticosteroids,

| TABLE 3 | Effect of corticosteroids on mortality of patients hospitalized with influenza A(H1N1)pdm09 viral pneumonia by multivariate Cox regression analysis |
|----------------|----------------|----------------|----------------|----------------|
|               | 30-Day Mortality |                 | 60-Day Mortality |                 |
|               |                  |                 |                  |                 |
|               | No. of Patientsa | Adjusted HR (95% CI) | P-value | No. of Patientsa | Adjusted HR (95% CI) | P-value |
| All patients  | Corticosteroids vs control | 232/1055 | 74/1086 | 0.80 (0.56-1.15) | .230 | 261/1055 | 76/1086 | 0.87 (0.61-1.24) | .433 |
|               | Low-to-moderate dose vs control | 113/662 | 74/1086 | 0.64 (0.43-0.96) | .033 | 130/662 | 76/1086 | 0.70 (0.47-1.04) | .078 |
|               | High-dose vs control | 114/367 | 74/1086 | 0.91 (0.58-1.44) | .694 | 126/367 | 76/1086 | 0.97 (0.62-1.51) | .882 |
| PaO2/FiO2 ≥300 mm Hg | Corticosteroids vs control | 17/295 | 12/686 | 2.43 (0.82-7.15) | .108 | 22/295 | 12/686 | 3.02 (1.06-8.58) | .038 |
|               | Low-to-moderate dose vs control | 14/226 | 12/686 | 3.09 (0.95-10.12) | .062 | 18/226 | 12/686 | 3.70 (1.20-11.34) | .022 |
|               | High-dose vs control | 3/55 | 12/686 | 1.70 (0.23-12.65) | .605 | 4/55 | 12/686 | 1.70 (0.23-12.65) | .605 |
| PaO2/FiO2<300 mm Hg | Corticosteroids vs control | 215/760 | 62/400 | 0.67 (0.46-0.98) | .038 | 239/760 | 64/400 | 0.68 (0.47-1.00) | .050 |
|               | Low-to-moderate dose vs control | 99/436 | 62/400 | 0.49 (0.32-0.77) | .002 | 112/436 | 64/400 | 0.51 (0.33-0.78) | .002 |
|               | High-dose vs control | 111/312 | 62/400 | 0.88 (0.56-1.39) | .581 | 122/312 | 64/400 | 0.92 (0.59-1.44) | .717 |

CI, confidence interval.

aShown as Events/Total.

FIGURE 2 Kaplan-Meier survival curves for matched patients treated with low-to-moderate-dose corticosteroids or with no corticosteroids (control), censored at 30 d. A, Including all the patients (n=530, log-rank chi-squared=10.48, P=.001), the 30-day mortality in the low-to-moderate dose corticosteroid group and control group was 6.8% (18/265) and 14.7% (39/265), respectively. B, Including patients with PaO2/FiO2<300 mm Hg (n=351, log-rank chi-squared=13.24, P<.001), the 30-day mortality in the low-to-moderate-dose corticosteroid group and control group was 8.1% (14/173) and 20.2% (36/178), respectively. C, Including patients with PaO2/FiO2≥300 mm Hg (n=179, log-rank chi-squared=0.17, P=.68), the 30-day mortality in the low-to-moderate-dose corticosteroid group and control group was 4.3% (4/92) and 3.4% (3/87), respectively.
including timing of antiviral therapy and timing of hospitalization, were well balanced between the patients in the propensity score-matched corticosteroid group and that in the control group (Table S5 and Table S6).

Kaplan-Meier survival curves (Figure 2A) for the propensity score-matched low-to-moderate-dose corticosteroid group and control group showed that 30-day mortality in the corticosteroid group was significantly lower than that in the control group (log-rank chi-squared=10.48, \( P = .001 \)). In subgroup analysis, this difference in mortality between the two groups was even more significant when only patients with \( \text{PaO}_2/\text{FiO}_2 < 300 \text{ mm Hg} \) on admission were assessed (log-rank chi-squared=13.24, \( P < .001 \); Figure 2B). However, the difference was not significant when only patients with \( \text{PaO}_2/\text{FiO}_2 \geq 300 \text{ mm Hg} \) on admission were taken into account (log-rank chi-squared=0.17, \( P = .683 \); Figure 2C). Similar results were observed for survival analysis censored at 60 days (Fig. S1).

Neither the 30-day (Figure 3) nor the 60-day mortality (Fig. S2) was significantly different between the propensity score-matched high-dose corticosteroid group and the control group. Only 20 patients with \( \text{PaO}_2/\text{FiO}_2 \geq 300 \text{ mm Hg} \) were given high-dose corticosteroid therapy, and one death occurred; therefore, subgroup analysis was not feasible for these patients.

3.5 | Effect of corticosteroid treatment on nosocomial infection

Nosocomial infection occurred 21.5% (227/1055) of patients in the corticosteroid group, which was significantly higher than that in the control group. Compared with the low-to-moderate-dose corticosteroid group, more patients in the high-dose corticosteroid group experienced nosocomial bacterial infection (16.8% vs 24.8%, \( P = .002 \)). The most common isolated pathogens were *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* (Table 4).

### DISCUSSION

Using a nationwide database comprising of 2141 hospitalized influenza A(H1N1)pdm09 viral pneumonia patients, among whom 89% were younger than 60 years, we found that severe influenza A(H1N1) pdm09 viral pneumonia patients with \( \text{PaO}_2/\text{FiO}_2 < 300 \text{ mm Hg} \) might benefit from low-to-moderate-dose corticosteroid. However, for the less severe patients with \( \text{PaO}_2/\text{FiO}_2 \geq 300 \text{ mm Hg} \), corticosteroid therapy might be harmful.

Corticosteroids were not recommended for patients with influenza infection by some guidelines. A considerable number of observational studies have shown that mortality rates in influenza-infected patients who received corticosteroid therapy were similar or even higher than that in patients who did not. In this study, univariate analysis also revealed that corticosteroid therapy was associated with increased mortality; however, patients who received corticosteroid therapy had more severe baseline disease (Table S5 and Table S6). Therefore, the higher mortality rate in corticosteroid group might just result from the more severe baseline condition of patients in this group. One study of influenza A(H1N1)pdm09 virus-infected patients with ARDS showed that low-to-moderate-dose corticosteroid (1 mg·kg\(^{-1}\)·d\(^{-1}\)) was associated with improvement of lung injury and reduced mortality. However, this conclusion was limited by a low number of cases.

To further explore whether corticosteroid therapy at a certain dose range is effective for a certain group of influenza pneumonia patients or not, we performed stratified analysis of patients with different disease severity, based on \( \text{PaO}_2/\text{FiO}_2 \) on admission. This stratification is of great importance, because \( \text{PaO}_2/\text{FiO}_2 \) is a key factor predicting mortality and may respond to corticosteroid use. In the present study, based on the largest dataset to date, we found that corticosteroids have a tendency to reduce mortality of patients with severe influenza A(H1N1) pdm09 viral pneumonia who have \( \text{PaO}_2/\text{FiO}_2 < 300 \text{ mm Hg} \). However, for patients with mild influenza A(H1N1)pdm09 viral pneumonia, with \( \text{PaO}_2/\text{FiO}_2 \geq 300 \text{ mm Hg} \), corticosteroids could not reduce mortality and their use was even associated with a higher 60-day mortality rate.
Despite being an important factor related to the efficacy of corticosteroids, dosage was mentioned in few studies published to date. In the current study, we further performed stratified analysis based on the doses of corticosteroids and found that only low-to-moderate dose of corticosteroids could lower the mortality rate in severe influenza A(H1N1)pdm09 viral pneumonia patients with PaO2/FiO2<300 mm Hg. The beneficial effect was not noticed in the large-dose corticosteroid group.

Except for the above factors, difference in study population might be another important element that contributed to the inconsistency between results revealed in this study and that published before. Compared to the study population in previous researches, patients enrolled in this study were much younger with a median age of just 34.4 years and fewer with underlying diseases. In both Kim and Brun’s study, the mean age of patients was more than 10 years older than patients in this study, and more than 80% of them had one or more comorbidities. And further the younger age and fewer underlying disease might lead to fewer secondary infection. Although compared to that in patients who did not receive corticosteroid therapy, the secondary infection rate was higher in the corticosteroid group, especially in the large-dose corticosteroid group, it was still much lower than that in the study by Kim, which reported that 57% of their total study population complicated secondary bacterial infection.

We further divided the patients into two groups based on their age as well as comorbidities. By multivariate Cox regression analysis, we found that corticosteroid showed no beneficial effect in influenza viral pneumonia patients aged >60 years or with comorbidities, while low-to-moderate corticosteroid therapy reduced mortality in severe influenza viral pneumonia patients (PaO2/FiO2<300 mm Hg) younger than 60 years and without any underlying disease (Table S7). Although the statistical power might not be potent enough to draw a robust conclusion, it gave us some hints that effect of corticosteroid might be influenced by age and underlying diseases of target population.

This study has some limitations. First, the intrinsic defects of retrospective studies were unavoidable, as confounding factors cannot be addressed completely. And the indication of corticosteroids and why the varied doses were used were not well recorded in the database. Although we tried to minimize the selection bias for corticosteroid use among different patients with propensity-matched analysis, only the known and measured confounders can be adjusted. Second, the effects of corticosteroids on viral shedding could not be assessed due to missing data. Third, in contrast to evaluation of a single dose in an RCT design, the dose in this study ranged from 25 to 150 mg. As body weights were not recorded in detail, doses of corticosteroids could not be calculated based on body weight.

Collectively, although we cannot avoid the possibility that the results might be skewed by the intrinsic limits of retrospective studies, our data should give some hints for future RCT studies. When considering an experimental therapy in influenza pneumonia patients, low-to-moderate dose corticosteroid should be tested preferably among the severe viral pneumonia patients with PaO2/FiO2<300 mm Hg.

### Table 4: Nosocomial infection of all 2141 patients hospitalized with influenza A(H1N1)pdm09 viral pneumonia

|                          | High-dose n=367 | Low-to-moderate n=662 | P-value | Corticosteroids n=1055 | Control n=1086 | P-value |
|--------------------------|-----------------|-----------------------|---------|------------------------|----------------|---------|
| Bacterial infections     | 91 (24.8)       | 111 (16.8)            | .002    | 202 (19.1)             | 43 (4.1)       | <.001   |
| Acinetobacter baumannii  | 25 (6.8)        | 47 (7.1)              | .862    | 72 (6.8)               | 13 (1.2)       | <.001   |
| Pseudomonas aeruginosa   | 16 (4.4)        | 13 (2.0)              | .026    | 29 (2.7)               | 4 (0.4)        | <.001   |
| Staphylococcus aureus    | 14 (3.8)        | 7 (1.1)               | .003    | 21 (2.0)               | 6 (0.6)        | .003    |
| Stenotrophomonas maltophilia | 8 (2.2)   | 9 (1.4)               | .323    | 17 (1.6)               | 1 (0.1)        | <.001   |
| Klebsiella pneumoniae    | 8 (2.2)         | 7 (1.1)               | .150    | 15 (1.4)               | 2 (0.2)        | .001    |
| Burkholderia cepacia     | 3 (0.8)         | 5 (0.8)               | 1.000   | 8 (0.8)                | 1 (0.1)        | .041    |
| Escherichia coli         | 2 (0.5)         | 5 (0.8)               | 1.000   | 7 (0.7)                | 1 (0.1)        | .070    |
| Enterobacter cloacae     | 2 (0.5)         | 3 (0.5)               | 1.000   | 5 (0.5)                | 2 (0.2)        | .426    |
| Moraxella catarrhalis    | 1 (0.3)         | 1 (0.2)               | 1.000   | 2 (0.2)                | 3 (0.3)        | 1.000   |
| Streptococcus pneumoniae| 0 (0.0)         | 2 (0.3)               | .541    | 2 (0.2)                | 2 (0.2)        | 1.000   |
| Haemophilus influenzae   | 2 (0.5)         | 2 (0.3)               | .939    | 4 (0.4)                | 0 (0.0)        | .126    |
| Enterobacter aerogenes   | 2 (0.5)         | 2 (0.3)               | .939    | 4 (0.4)                | 0 (0.0)        | .126    |
| Other bacteria           | 8 (2.2)         | 8 (1.2)               | .228    | 16 (1.5)               | 8 (0.7)        | .087    |
| Invasive fungal infections| 9 (2.5)       | 16 (2.4)              | .972    | 25 (2.4)               | 3 (0.3)        | <.001   |

Categorical variables were presented as number (percentage). Chi-squared test was used for comparison of patients from different groups.
ACKNOWLEDGEMENTS

The authors thank all the physicians of the 407 hospitals who treated the influenza A(H1N1)pdm09 viral pneumonia patients in local hospitals, involved in the data collection, and were not listed in the author list. This study was supported by the National Science Fund for Distinguished Young Scholars (81425001/H0104) for Dr. Bin Cao, grants from the National Key Technology Support Program from Ministry of Science and Technology (2015BAI12B11), as well as the Beijing Science and Technology Project (D151100002115004).

NOTATION OF PUBLICATION

This work has been accepted as a rapid oral poster presentation at the ISIRV-Options IX for the Control of Influenza Conference on June 24th-28th, 2016 at the Sheraton Grand Chicago Hotel, Chicago, USA.

REFERENCES

1. Yu X, Zhang X, Zhao B, et al. Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6. PLoS ONE. 2011;6:e28680.

2. Yang SQ, Qu JX, Wang C, Yu XM, Liu YM, Cao B. Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1)pdm09 and A (H3N2) in the post-pandemic period. Clin Respir J. 2014;8:185-191.

3. Zhao Y, Zhang YH, Denney L, et al. High levels of virus-specific CD4+ T cells predict severe pandemic influenza A virus infection. Am J Respir Crit Care Med. 2012;186:1292-1297.

4. Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel influenza A(H1N1) infection. Am J Pathol. 2010;177:166-175.

5. Shieh WJ, Blau DM, Denison AM, et al. 2009 pandemic influenza A (H1N1): pathogenesis and pathogenesis of 100 fatal cases in the United States. Am J Pathol. 2010;177:166-175.

6. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302:1896-1902.

7. Li C, Yang P, Zhang Y, et al. Corticosteroid treatment ameliorates acute lung injury induced by 2009 swine origin influenza A (H1N1) virus in mice. PLoS ONE. 2012;7:e44110.

8. Ottolini M, Blanco J, Porter D, Peterson L, Curtis S, Prince G. Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model. Pediatr Pulmonol. 2003;36:290-294.

9. Quispe-Laime AM, Bracco JD, Barberio PA, et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med. 2010;36:33-41.

10. Lee KY, Rhim JW, Kang JH. Hyperactive immune cells (T cells) may be responsible for acute lung injury in influenza virus infections: a need for early immune-modulators for severe cases. Med Hypotheses. 2011;76:64-69.

11. Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1) virus influenza A infection. Intensive Care Med. 2011;37:272-283.

12. Diaz E, Martin-Loeches I, Canadell L, et al. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J Infect. 2012;64:311-318.

13. Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med. 2011;183:1207-1214.

14. Brun-Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183:1200-1206.

15. Annane D. Pro: the illegitimate crusade against corticosteroids for severe H1N1 pneumonia. Am J Respir Crit Care Med. 2011;183:1125-1126.

16. Matthay MA, Liu KD. Con: corticosteroids are not indicated for treatment of acute lung injury from H1N1 viral pneumonia. Am J Respir Crit Care Med. 2011;183:1127-1128.

17. Delaney JW, Pinto R, Long J, et al. The influence of corticosteroid treatment on the outcome of influenza (A/H1N1pdm09)-related critical illness. Crit Care. 2016;20:75.

18. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492-500.

19. Giannella M, Alonso M, Garcia de Viedma D, et al. Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients. Clin Microbiol Infect. 2011;17:1160-1165.

20. World Health Organization. (2009) Clinical management of human infection with pandemic (H1N1) 2009: revised guidance, November 2009. Accessed at: http://www.who.int/csr/resources/publications/swineflu/clinical_management_h1n1. Date last updated: November 2009. Accessed: January, 2016.

21. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam JS, Lim WS. Effect of Corticosteroid Therapy on Influenza-Related Mortality: A Systematic Review and Meta-analysis. J Infect Dis. 2015;212:183-194.

22. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313:677-686.

23. Blum CA, Nigo N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385:1511-1518.

24. Tagami T, Matsu H, Horiguchi H, Fushimi K, Yasunaga H. Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. Eur Respir J. 2015;45:463-472.

25. Li F, Chen G, Wang J, Liu H, Wu J. A case-control study on risk factors associated with death in pregnant women with severe pandemic H1N1 infection. BMJ Open. 2012;2:1-6.

26. Linko R, Pettila V, Ruokonen E, et al. Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland. Acta Anaesthesiol Scand. 2011;55:1511-1518.

27. Mady A, Ramadan OS, Yousef A, Mandourah Y, Amr AA, Kherallah M. Clinical experience with severe 2009 H1N1 influenza in the intensive care unit at King Saud Medical City, Saudi Arabia. J Infect Public Health. 2012;5:52-56.

28. Sertogullarindan B, Ozbay B, Gunin H, et al. Clinical and prognostic features of patients with pandemic 2009 influenza A(H1N1) virus in the intensive care unit. Afr Health Sci. 2011;11:163-170.

29. Viasus D, Pano-Pardo JR, Cordero E, et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) virus in the intensive care unit. AFR Health Sci. 2011;11:163-170.

30. Lamontagne F, Briel M, Guyatt GH, Cook DJ, Bhatnagar N, Meade M. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care. 2010;25:420-435.
syndrome: a systematic review and meta-analysis. Crit Care Med. 2009;37:1594-1603.
33. Wang C, Yu H, Horby PW, et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis. 2014;58:1095-1103.
34. Yang SG, Cao B, Liang LR, et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS ONE. 2012;7:e29652.
35. Lee N, Leo YS, Cao B, et al. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J. 2015;45:1642-1652.
36. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-1821.
37. Shi SJ, Li H, Liu M, et al. Mortality prediction to hospitalized patients with influenza pneumonia: PO/FiO combined lymphocyte count is the answer. Clin Respir J. 2017;11:352-360.
38. Metersky ML, Masterton RG, Lode H, File TM Jr, Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012;16:e321-e331.
39. Pillai PS, Molony RD, Martinod K, et al. Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease. Science. 2016;352:463-466.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.